NEW YORK – Chinese molecular diagnostic firm Dinfectome said on Monday that its DIFSeq-200 sequencer has obtained approval from the Chinese National Medical Products Administration (NMPA).
According to Dinfectome, the desktop sequencer employs a combination of probe-anchored synthesis and DNA nanoball sequencing technology, the same technology used by MGI Tech’s instruments. It can be paired with lab automation instruments and the so-called Gensis bioinformatics pipeline to perform in-hospital next-generation sequencing tests to help guide therapy selection. An MGI spokesperson said Dinfectome licensed the DNA nanoball sequencing technology from the company.
Dinfectome said the DIFSeq-200 can achieve a Q30 score, the probability of an incorrect base call 1 in 1000 times, for more than 85 percent of bases while generating multiple read lengths. The output of the platform is between 10 Gb and 150 Gb per run. According to the firm, the platform is suitable for applications including prenatal screening, tumor mutation detection, and pathogen identification.
Established in 2018 and headquartered in the Chinese southern city of Nanjing, Dinfectome said it focuses on the research, development, and provision of clinical molecular testing for pathogens. Earlier this year, the company inked a collaboration agreement with MGI Tech to jointly promote the use of the DNBSeq-G99 sequencer for pathogenic microorganism detection, according to Dinfectome’s website.